> Invitrogen of Carlsbad, California, has acquired Quantum Dot and Biopixels for an undisclosed amount. The acquisitions are intended to bolster Invitrogen's molecular probes business. Release
> Pfizer's breast cancer drug Aromasin has been given expanded approval as a therapy following surgery for early breast cancer. Article
> The bio-nanotech company pSivida of Perth, Australia, has secured $15 million in new funding. Release
> Chiron and Nektar Therapeutics have begun a Phase III trial evaluating tobramycin inhalation powder, an investigational inhaled antibiotic. Report
> Canada's Trillium Therapeutics has acquired all of the assets of Arthron, a subsidiary of Prima Biomed. Release
> Chutes & Ladders: Jay M. Short, Ph.D., has resigned as CEO and a member of Diversa's board of directors by mutual agreement with the board. Release
> Siga Technologies said that an animal study of its smallpox compound produced promising results. Release
And Finally... Toll-like receptors have become a hot commodity in new research as companies explore the therapeutic potential of an immune response. Article